Table 1 Baseline patient characteristics by treatment
| Patient, treatment and tumour characteristics | TARGIT-IORT | EBRT |
|---|---|---|
| Number of patients (% of total) | 60 (48%) | 66 (52%) |
|
Age (mean years +/− SD)
Range |
63 (+/− 8.2) 50–83 |
62 (+/− 7.4) 50–80 |
|
Randomised prepathology (before WLE)
Randomised postpathology (after WLE) |
4 (7%) 56 (93%) |
14 (21%) 52 (79%) |
| Baseline assessments prior to any surgery N (% of treatment group) | 2 (3%) | 12 (18%) |
|
Baseline BMI (mean score kg/m
2
+/− SD)
Baseline BMI Group a (% pf treatment group) | 29 (+/− 5.5) | 30 (+/− 5.9) |
| 1 – Underweight (< 18.5) | 0% | 0% |
| 2 – Normal (18.5–24.99) | 30% | 16% |
| 3 – Overweight (25–29.99) | 30% | 50% |
| 4 – Obese (30+) | 40% | 34% |
|
Tumour Size (mm mean ± SD)
Tumour Size Group, % of treatment group | 10 (+/− 4.2) | 11 (+/− 5.0) |
| < 11(mm) | 62% | 52% |
| 11–20 (mm) | 38% | 46% |
| > 21(mm) b | – | 1.5% |
| Tumour Grade, n (% of treatment group) | ||
| 1 | 37 (62%) | 38 (57%) |
| 2 | 23 (38%) | 27 (41%) |
| 3b | 0 | 1 (1.5%) |
| Tumour Type, n (% of treatment group) | ||
|
IDC Mixed IDC/ILCb |
59 (98%) 1 (1.7%) |
64 (97%) 2 (3%) |
| Lesions, n (% of treatment group) | ||
| 1 | 60 (100%) | 65 (98%) |
| 2b | 0 | 1 (1.5%) |
| Extensive DCIS (> 25% of tumour + inside and out of tumour) b n (% of treatment group) | 0 | 4 (6.3%) |
| Hormone receptor status, n (% of treatment group) | ||
| ER + ve | 60 (100%) | 64 (97%) |
| PR + ve | 44 (73%) | 52 (79%) |
| ER and PR –ve b | 0 | 2 (3%) |
| Positive Nodes b , n (% of treatment group) | 0 | 1 (1.5%) (1 node) |
|
Largest Specimen Length (mean -mm +/− SD)
Range |
89 (+/− 37.2) 25–205 |
89 (+/− 38.4) 40–267 |
| Extent of Axillary Surgery, n (% of treatment group) | ||
| Nil | 3 (5%) | 2 (3%) |
| SLNBx | 49 (82%) | 55 (83%) |
| Clearance | 8 (13%) | 9 (14%) |
| Further Surgery Required, n (% of treatment group) | ||
| SLNBx | 2 (3.3%) | 2 (3%) |
| Margins | 2 (3.3%) | 7 (11%) |
| Revision of Scar | 2 (3.3%) | 0 |
| Radiotherapy Dose Range (Gy) | 16-33c | 45–50.4 |
| Fractions (range) | 1 | 25 (25–28) |
| Boost Given (20Gy in 10 fractions), n (% of treatment group) | N/A | 11 (17%) |
| Supraclavicular Treatment, n (% of treatment group) | N/A | 1 (1.5%) |
| Chemotherapy given b (n, % of treatment group) | 0 | 1 (1.5%) |
| Baseline Cosmesis Scores (% Excellent-Good), mean (± SD) | ||
| Patient Harris | 85 (+/− 0.36) | 82 (+/− 0.39) |
| Nurse Harris | 93 (+/− 0.25) | 92 (+/− 0.27) |
| Doctor Harris† | 87 (+/− 0.35) | 100 (+/− 0.0) |
| BCCT.Core | 83 (+/− 0.38) | 90 (0.31) |
